AVENIO ctDNA Surveillance Kit – Longitudinal Tumor Burden Monitoring

Material Number: N/A

Next-generation sequencing (NGS) liquid biopsy assay specially designed to monitor tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease (MRD). Contains 471 frequently mutated regions associated with the presence of disease across 197 genes.

Technical Datasheet: Technical datasheet

Description

The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy assay that’s specially designed and optimized for longitudinal tumor burden monitoring in lung cancer and colorectal cancer (CRC). The Surveillance panel contains 197 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1

 

Specifications:

  • Panel size: 198 kb
  • Sample size: 4 ml of plasma
  • ctDNA input 10-50 ng
  • Reactions per kit: 16
  • Turn-around time: 5 days from extraction to results

Product Highlight: Detection of mutants with exceptional sensitivity and specificity2,3 with >99% specificity for all classes of mutations and >99% positive predictive value (PPV) for SNVs, indels, and fusions and A96% PPV for CNVs.

The present kit includes the following subkits:
For more information or further assistance, please reach out to our local representative through the contact form.

Table demonstrating the performance of AVENIO ctDNA kits

The AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research. These assays provide an end-to-end tumor profiling and longitudinal tumor burden monitoring solution.

References:

  1. National Comprehensive Cancer Network. October 15, 2016
  2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519
  3. Data on file.